March 2nd Week, 2025 Mergers & Acquisitions 🤝 Checkpoint Therapeutics Inc is set to be acquired by SUN PHARMA, an Indian pharma giant. This deal will strengthen Sun Pharma’s onco-dermatology portfolio, as it includes Unloxcyt (cosibelimab-ipdl), an FDA-approved anti-PD-L1 treatment indicated for advanced cutaneous squamous cell carcinoma (cSCC) (Ref 1) ❓ How will this acquisition position Sun Pharma in the immuno-oncology space? What is the indication expansion strategy for